MARKET

REPH

REPH

Recro Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.850
-0.110
-5.61%
After Hours: 1.850 0 0.00% 16:32 10/26 EDT
OPEN
1.950
PREV CLOSE
1.960
HIGH
2.000
LOW
1.830
VOLUME
333.53K
TURNOVER
--
52 WEEK HIGH
19.21
52 WEEK LOW
1.830
MARKET CAP
43.73M
P/E (TTM)
-10.4875
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
The Daily Biotech Pulse: Mesoblast Slumps On FDA Rejection, AstraZeneca's Breakthrough Therapy Designation, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 1)
Benzinga · 10/02 11:35
Recro to Present at Oppenheimer Fall Healthcare Life Sciences & Medtech Summit
GAINESVILLE, Ga., Sept. 18, 2020 (GLOBE NEWSWIRE) -- Recro (Nasdaq:REPH), a leading contract development and manufacturing organization (CDMO), with integrated solutions for the development, formulation, regulatory support, manufacturing and packaging of oral solid dose drug products, today announced
GlobeNewswire · 09/18 12:30
The Daily Biotech Pulse: AbbVie In-licenses I-Mab's Cancer Drug, Savara Pulls The Plug On Cystic Fibrosis Study
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 3)
Benzinga · 09/04 11:28
The Daily Biotech Pulse: Pfizer-BioNTech Vaccine Data, Sorrento To Buy R&D Partner, Kymera IPO
  Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 20)
Benzinga · 08/21 11:43
The Daily Biotech Pulse: Mesoblast Awaits Adcom Test, BioCryst Rallies On Insider Buying, Sorrento Hits Back At Short Seller
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 12)
Benzinga · 08/13 12:18
The Daily Biotech Pulse: Regulatory Setback For Fennec Pharma, Ligand To Buy Pfenex, Inovio Says Phase 2/3 Coronavirus Vaccine Study Starts In September
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10)
Benzinga · 08/11 12:20
Q2 miss pressures Recro Pharma, down 26%
Nano cap Recro Pharma (REPH -25.6%) slumps on more than double normal volume after announcing less-than-expected Q2 results. Highlights: Revenue down 50% t
seekingalpha · 08/10 20:15
Recro Pharma EPS misses by $0.09, misses on revenue
Recro Pharma (NASDAQ:REPH): Q2 GAAP EPS of -$0.25 misses by $0.09. Revenue of $15.5M (-50.4% Y/Y) misses by $3.38M. Press Release
seekingalpha · 08/10 16:03
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of REPH. Analyze the recent business situations of Recro Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average REPH stock price target is 7.50 with a high estimate of 10.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 141
Institutional Holdings: 18.97M
% Owned: 80.26%
Shares Outstanding: 23.64M
TypeInstitutionsShares
Increased
31
2.56M
New
40
-419.80K
Decreased
29
2.07M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.74%
Pharmaceuticals & Medical Research
-0.94%
Key Executives
Chairman/Independent Director
Wayne Weisman
President/Chief Executive Officer/Director
Geraldine Henwood
Chief Financial Officer
Ryan Lake
Executive Vice President
Jyrki Mattila
Independent Director
William Ashton
Independent Director
Michael Berelowitz
Independent Director
Winston Churchill
Independent Director
Bryan Reasons
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About REPH
Recro Pharma, Inc. is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company's lead product candidate is an injectable form of meloxicam. Its product candidates for pain indications include injectable meloxicam, a product candidate in development for the treatment of acute post-operative pain; Dex-IN, a product candidate under development for the treatment of post-operative pain; Dex-SL, a product candidate for the treatment of chronic pain, and Fadolmidine (Fado), a product candidate used by injection into the spine for pain associated with surgery or certain types of chronic pain and which the Company pursues as a topical product for local application to treat serious pain associated with nerve damage to local tissues (neuropathies), especially of the lower extremities, which can occur in diabetic patients.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Recro Pharma Inc stock information, including NASDAQ:REPH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, REPH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading REPH stock methods without spending real money on the virtual paper trading platform.